← Back to Search

Photoacoustic Imaging for Lymph Node Cancer

Phase < 1
Waitlist Available
Led By Priya R Bhosale
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Scheduled to undergo ultrasound-guided fine needle aspiration cytology or biopsy
Pathologically proven primary malignancy
Must not have
The deeper inguinal lymph nodes (3-5 cm deep) and smaller (< 1 cm in short axis) in dimensions will be excluded from the study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 months
Awards & highlights
No Placebo-Only Group

Summary

This trial uses ultrasound & light to detect cancer in groin lymph nodes, which may help prevent unnecessary surgery.

Who is the study for?
This trial is for cancer patients with suspicious groin lymph nodes identified by standard imaging and scheduled for needle aspiration or biopsy. It's not suitable for melanoma patients or those with deep (3-5 cm) or small (<1 cm) lymph nodes.
What is being tested?
The study tests ultrasound-guided photoacoustic imaging to distinguish between healthy and cancerous groin lymph nodes, aiming to improve tumor staging and reduce unnecessary surgeries.
What are the potential side effects?
As a non-invasive imaging technique, ultrasound-guided photoacoustic imaging has minimal side effects, primarily related to the discomfort from the ultrasound procedure itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for a needle biopsy guided by ultrasound.
Select...
My cancer diagnosis was confirmed through a biopsy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My lymph nodes are not deep (3-5 cm) or small (<1 cm) enough to be excluded.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Difference between background oxygen saturation (%sO2) and nodal %sO2

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)Experimental Treatment5 Interventions
Patients undergo standard of care ultrasound of the lymph nodes, then undergo ultrasound-guided PAI over 3-5 minutes. Patients then undergo standard of care ultrasound-guided FNA or biopsy a suspicious lymph node.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fine-Needle Aspiration
2018
Completed Early Phase 1
~40
Lymph Node Biopsy
2014
Completed Phase 2
~50
Ultrasound
2013
Completed Phase 1
~4090

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,066 Previous Clinical Trials
1,802,222 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,925 Previous Clinical Trials
41,017,978 Total Patients Enrolled
Priya R BhosalePrincipal InvestigatorM.D. Anderson Cancer Center
3 Previous Clinical Trials
20,071 Total Patients Enrolled

Media Library

Multispectral optoacoustic tomography (MSOT) acuity instrument Clinical Trial Eligibility Overview. Trial Name: NCT04185337 — Phase < 1
Cancer Research Study Groups: Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)
Cancer Clinical Trial 2023: Multispectral optoacoustic tomography (MSOT) acuity instrument Highlights & Side Effects. Trial Name: NCT04185337 — Phase < 1
Multispectral optoacoustic tomography (MSOT) acuity instrument 2023 Treatment Timeline for Medical Study. Trial Name: NCT04185337 — Phase < 1
~3 spots leftby Jun 2025